TWST

TWST

USD

Twist Bioscience Corporation Common Stock

$40.110+0.390 (0.982%)

リアルタイム価格

Healthcare
Diagnostics & Research
米国

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$39.720

高値

$40.590

安値

$39.060

出来高

0.00M

企業ファンダメンタルズ

時価総額

2.4B

業種

Diagnostics & Research

United States

取引統計

平均出来高

1.17M

取引所

NMS

通貨

USD

52週レンジ

安値 $30.32現在値 $40.110高値 $60.9

AI分析レポート

最終更新: 2025年4月22日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

TWST (Twist Bioscience Corporation Common Stock): What's Happening and What to Watch

Stock Symbol: TWST Generate Date: 2025-04-22 20:53:32

Alright, let's break down what's been going on with Twist Bioscience stock and what the tea leaves might be suggesting. We'll look at the latest news, how the price has been acting, and what some of the automated tools are predicting.

The Latest News Buzz

So, the main piece of news we've got is from Barclays, a pretty big bank. Their analyst, Luke Sergott, still thinks Twist Bioscience is a stock you should probably hold onto – they kept their "Overweight" rating. That's generally a good sign; it means they see potential here.

But, and this is a key point, they did lower their price target. They used to think the stock could hit $58, but now they're saying $45. What does that tell us? It's a bit of a mixed signal. They haven't given up on the company, which is positive. However, they're less optimistic about just how much it's likely to climb in the near future. Think of it like a coach still believing in the team but maybe adjusting their expectations for the next few games.

Checking the Price Action

Looking at the stock's journey over the past couple of months, it's been quite a ride. Back in late January and early February, shares were trading up in the $50-$55 range. Things took a noticeable dip through February and into early March, dropping into the high $30s and low $40s. March saw a bit of a bounce, getting back into the mid-$40s briefly.

More recently, in April, we saw another slide, with the price hitting lows around $33-$34. As of the last data point (April 22nd), the stock closed around $36.94. So, the overall trend from the start of the year has been downwards, but it seems to have found some sort of floor in the mid-$30s lately.

Now, let's peek at what the AI prediction model is saying for the very short term. It predicts the price will be essentially flat today (0.0% change), but then sees a potential upward move of about 4% tomorrow and another 4% the day after. That suggests the AI thinks this recent stability in the mid-$30s could be a springboard for a small bounce.

Putting It All Together: What Might Be Next?

Based on the news, the recent price moves, and the AI's short-term forecast, here's one way to look at it:

The analyst still likes the stock overall, even with a lower target. The price has taken a hit but seems to be trying to stabilize around the mid-$30s. The AI model is actually predicting a small upward push from here in the next couple of days.

This combination might suggest a cautiously positive leaning for the very near term. It doesn't scream "buy everything now," but it doesn't necessarily say "run for the hills" either.

  • Potential Entry Consideration: If you were thinking about this stock, the current price area in the mid-$30s, especially if it dips back towards those recent lows around $34, could be a point of interest. This aligns with where the AI sees a potential bounce starting.
  • Potential Exit/Stop-Loss Consideration: Managing risk is always smart. The recommendation data points to $31.08 as a potential stop-loss level. This is below the recent lows and could be a place to consider cutting losses if the price breaks down significantly. For taking profits, the analyst's new target of $45 is out there as a longer-term goal. For the very short term, if the AI's prediction plays out, you might look for a move towards the upper end of the recent range, perhaps the low $40s, but that's just speculation based on past volatility.

A Little Company Context

Remember, Twist Bioscience is in the Healthcare sector, specifically Diagnostics & Research. They make synthetic DNA products. This is a high-tech, often volatile space. The company isn't profitable yet (that's what the negative P/E ratio tells us), which is common for growth companies in this field, but it means their stock price can react strongly to news about their technology, sales, or the broader biotech market. They're a mid-size company with a market cap around $2.3 billion.

Important Disclaimer: This analysis is purely for informational purposes based on the provided data. It's not financial advice. Stock markets are risky, and prices can go down as well as up. Always do your own thorough research or talk to a qualified financial advisor before making any investment decisions.

関連ニュース

BusinessWire

Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System

Adds to robust offering of NGS tools enabling exome sequencing, whole genome sequencing, RNA sequencing, deep sequencing for liquid biopsy research and MRD, and methylation detection Diverse portfolio of adapter sets

もっと見る
Twist Bioscience Expands Universal Adapter Portfolio with Launch of High Throughput UDI Adapter System
Analyst Upgrades

Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

Barclays analyst Luke Sergott maintains Twist Bioscience with a Overweight and lowers the price target from $58 to $45.

もっと見る
Barclays Maintains Overweight on Twist Bioscience, Lowers Price Target to $45

AI予測Beta

AI推奨

強気

更新日時: 2025年4月28日 10:04

弱気中立強気

65.9% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
バリュー成長アグレッシブ
取引ガイド

エントリーポイント

$40.24

利確

$44.00

損切り

$36.14

主要因子

DMIは弱気トレンドを示しており (ADX:13.6、+DI:11.7、-DI:12.7)、注意が必要です
現在の価格はサポートレベル(40.18ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(13,325)の4.3倍で、極めて強い買い圧力を示しています
MACD -0.0266はシグナルライン0.0231の下にあり、弱気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。